Building Clinical Trial Capacity in Pakistan: From Untapped Potential to Global Research Competitiveness
Proceedings · 10.11.2026 · 40 (3) · 256-258
DOI: 10.47489/szmc.v40i3.1081 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings, online erschienen am 10.11.2026. Verfasst von Ayesha Humayun und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Every clinician carries memories of particular patients.Some are of relief, when a new treatment worked.Others are of loss, when there was no effective therapy to offer.Both leave the same question behind: could we have done better, or known more?Clinical trials are how medicine answers it.A vaccine that protects our children, a targeted therapy that shrinks a tumor, a simple drug that turns a chronic illness into a manageable one: each reached patients only after the long and demanding work of clinical research.That work is not evenly shared.Fewer than half of the clinical trials run by the world's largest pharmaceutical companies take place in lowand middle-income countries (LMICs), even though these countries are home to nearly 80% of the global population [1] Pakistan has, for too long, used evidence generated elsewhere instead of helping to create it. The Clinical Trial Landscape in PakistanClinical research in Pakistan has historically been concentrated in a small number of academic institutions and tertiary care hospitals.A review of trials conducted in Pakistan between 2000 and 2022 found that interventional research is held back by limited funding, a shortage of skilled personnel, and regulatory obstacles, and that most trial funding comes from Western funders or pharmaceutical companies [2] .Pakistan's medical research output has grown quickly: Scopus-indexed medical publications roughly tripled between 2001-2010 and 2011-2020, and in 2019-2020 Pakistan had the second-highest publication growth rate of 46 countries analyzed [3] .Much of that growth, however, has been in observational studies and surveys.These have real value, yet they cannot answer the questions that only randomized trials can.Pakistan's share of international multicenter trials remains small for a country of its size, and worldwide, the growth in registered trials has been uneven across regions [2,4] .The COVID-19 pandemic showed both what Pakistan can do and how narrow its base still is.The international phase 3 trial of the single-dose Ad5-nCoV vaccine began enrolling in Pakistan in September 2020, before any other country, and Pakistan contributed the largest national share of participants to the efficacy analysis [5] .That achievement was the exception rather than the rule; the funding, staffing, and regulatory barriers described above still limit most institutions [2] . Why Pakistan MattersPakistan's value as a trial location starts with its population.Recruitment is one of the hardest parts of any clinical trial, and Pakistan's large and varied population gives access to patients across many disease areas.The country carries a heavy burden of infectious disease alongside rising rates of diabetes, cardiovascular disease, cancer, and mental disorders, which makes a wide range of therapeutic studies possible.Its tertiary teaching hospitals see high patient volumes and complex cases, and many of their clinicians have the expertise to contribute to international research collaborations.From Potential to Preparedness Moving from potential to preparedness starts with institutional commitment.Research is usually treated as the business of individual investigators, but a sustainable trial program needs an institution that owns it.Hospital leaders have to treat research as a strategic priority: commit dedicated resources, set up governance structures, and build research goals into the institutional plan.Ethical oversight matters just as much, because clinical research depends on public trust.Institutional review boards must review protocols rigorously, work
Zitieren
APA
Humayun, A., Malik, S., & Ayub, E. (2026). Building Clinical Trial Capacity in Pakistan: From Untapped Potential to Global Research Competitiveness. Proceedings, 40(3), 256-258. https://doi.org/10.47489/szmc.v40i3.1081
Vancouver
Humayun A, Malik S, Ayub E. Building Clinical Trial Capacity in Pakistan: From Untapped Potential to Global Research Competitiveness. Proceedings. 2026;40(3):256-258. doi:10.47489/szmc.v40i3.1081
BibTeX
@article{Humayun2026,
author = {Humayun, Ayesha and Malik, Salma and Ayub, Eman},
title = {Building Clinical Trial Capacity in Pakistan: From Untapped Potential to Global Research Competitiveness},
journal = {Proceedings},
year = {2026},
volume = {40},
number = {3},
pages = {256--258},
doi = {10.47489/szmc.v40i3.1081}
}
EUVIMED